Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785920 | 1.00 | ALDH1A1 (0.47) | ALDH1A1TAS1R3TAS1R1TAS1R2PYGL | |
| SCHEMBL2816083 | 0.89 | ALDH1A1 (0.44) | ALDH1A1TAS1R3TAS1R1TAS1R2SPTLC2 | |
| SCHEMBL803181 | 0.89 | ALDH1A1 (0.44) | ALDH1A1TAS1R3TAS1R1TAS1R2SPTLC2 | |
| SCHEMBL13190098 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TAS1R3TAS1R1TAS1R2PYGL | |
| SCHEMBL484844 | 0.82 | ALDH1A1 (0.49) | ALDH1A1TAS1R3TAS1R1TAS1R2PYGL | |
| SCHEMBL784762 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TAS1R3TAS1R1TAS1R2PYGL | |
| SCHEMBL785599 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TAS1R3TAS1R1TAS1R2PYGL | |
| SCHEMBL784976 | 0.82 | ALDH1A1 (0.49) | ALDH1A1TAS1R3TAS1R1TAS1R2PYGL | |
| SCHEMBL784602 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TAS1R3TAS1R1TAS1R2PYGL | |
| SCHEMBL784603 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TAS1R3TAS1R1TAS1R2PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | ALDH1A1 2086/4885TAS1R3 339/4885TAS1R1 107/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | ALDH1A1 2086/4885TAS1R3 339/4885TAS1R1 107/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | ALDH1A1 1267/4885TAS1R3 202/4885TAS1R1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.